Automating Raw Materials Processes in CGT Manufacturing

Question Title

* 1. What stage are you at in the development of your therapy?

Pre-clinical

Phase I

Phase II

Phase III

Post-trials/marketing

N/A

Question Title

* 2. Do you develop an autologous or allogeneic cell therapy or both?

Autologous

Allogeneic

Both

Question Title

* 3. Have you automated (all or part of) your cell therapy manufacturing process or are you planning to do so in the future?

Our manufacturing process is fully automated

Part of our manufacturing process is automated

We are planning to implement automated processes in 1-2 years

We are planning to implement automated processes in 3-5 years

We have not thought about automation yet

Question Title

* 4. Will you setup your automated cell therapy manufacturing process in-house or at a CDMO/CMO?

In-house

CDMO/CMO

Question Title

* 5. Which of the following is your preferred type of manufacturing platform?

Single, closed-cell therapy manufacturing platform

Flexible/modular cell therapy manufacturing platform

Question Title

* 6. What are your biggest raw material challenges? (choose multiple)

Closed-system connectivity

Supply chain issues

No GMP grade available

Varying regulatory requirements

Dependence on a sole supplier

Lot-to-lot variability

High costs

Safety of the raw material

Other (please specify)

Question Title

* 7. Which raw material characteristics would enable you to automate your raw material processes? (choose multiple)

Closed system connectivity

Simplified connectivity

Eliminate reconstitution step

A dry-powder formulation for in-house processing/reconstitution

Desired concentration

Global standardisation

Pre-mixed ready-to-use reagents

Other (please specify)

Question Title

* 8. Which of the above would offer the most benefit? (choose one)

Closed system connectivity

Simplified connectivity

Eliminate reconstitution step

A dry-powder formulation for in-house processing/reconstitution

Desired concentration

Global standardisation

Pre-mixed ready-to-use reagents

Other (please specify)

Question Title

* 9. Which of the following best describes the scientific area you work in?

Pharmaceutical or biotech company

Academic

CDMO/CMO/CRO

Hospital/clinic

Government

Biobank

Consultancy

Raw material/service provider

Question Title

* 10. Which of the following best describes your job title?

Scientist

Manager

Engineer

Director/VP/CEO

Medical doctor/clinician

Advisor/consultant

Other (please specify)

Question Title

* 11. Contact information - we will share the results with you once the survey has closed.

Name

Company

Country

Email Address

Automating Raw Materials Processes in CGT Manufacturing

Question Title

* 1. What stage are you at in the development of your therapy?

Question Title

* 2. Do you develop an autologous or allogeneic cell therapy or both?

Question Title

* 3. Have you automated (all or part of) your cell therapy manufacturing process or are you planning to do so in the future?

Question Title

* 4. Will you setup your automated cell therapy manufacturing process in-house or at a CDMO/CMO?

Question Title

* 5. Which of the following is your preferred type of manufacturing platform?

Question Title

* 6. What are your biggest raw material challenges? (choose multiple)

Question Title

* 7. Which raw material characteristics would enable you to automate your raw material processes? (choose multiple)

Question Title

* 8. Which of the above would offer the most benefit? (choose one)

Question Title

* 9. Which of the following best describes the scientific area you work in?

Question Title

* 10. Which of the following best describes your job title?﻿

Question Title

* 11. Contact information - we will share the results with you once the survey has closed.

* 10. Which of the following best describes your job title?